XML 15 R54.htm IDEA: XBRL DOCUMENT v2.4.0.6
Income Taxes (Details) (USD $)
12 Months Ended 12 Months Ended 12 Months Ended 3 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Mar. 31, 2010
Provision
Dec. 31, 2012
Internal Revenue Service (IRS) [Member]
Dec. 31, 2011
Internal Revenue Service (IRS) [Member]
Dec. 31, 2012
State Jurisdiction [Member]
Dec. 31, 2011
State Jurisdiction [Member]
Sep. 30, 2012
Internal Revenue Service (IRS) [Member]
Dec. 31, 2012
Internal Revenue Service (IRS) [Member]
Dec. 31, 2012
State Jurisdiction [Member]
Dec. 31, 2012
State Jurisdiction [Member]
Prescription Drug Tax Benefit and Medicare Part D [Abstract]                        
Income tax expense (benefit) related to retiree prescription drug benefits $ (17,000,000)                      
Number of applicable provisions addressing deductibility of retiree health care costs       1                
Tax Audits [Abstract]                        
Year(s) no longer subject to audit as statute of limitations has expired                   2008    
Earliest year subject to examination                   2009 2006 2006
Year(s) under examination                 2010 and 2011   2006 through 2009 None
Unrecognized Tax Benefits [Abstract]                        
Unrecognized tax benefit - Permanent tax positions 1,300,000 500,000                    
Unrecognized tax benefit - Temporary tax positions 8,300,000 10,900,000                    
Total unrecognized tax benefit 9,600,000 11,400,000 11,600,000                  
Reconciliation of Unrecognized Tax Benefits [Roll Forward]                        
Balance at Jan. 1 11,400,000 11,600,000 7,200,000                  
Additions based on tax positions related to the current year 1,900,000 3,400,000 4,100,000                  
Reductions based on tax positions related to the current year (1,500,000) (800,000) (200,000)                  
Additions for tax positions of prior years 2,000,000 5,800,000 1,600,000                  
Reductions for tax positions of prior years (4,200,000) (900,000) (1,100,000)                  
Settlements with taxing authorities 0 (7,700,000) 0                  
Balance at Dec. 31 9,600,000 11,400,000 11,600,000                  
Tax Benefits Associated With Nol And Tax Credit Carryforwards [Abstract]                        
NOL and tax credit carryforwards (5,300,000) (3,700,000)                    
Amounts accrued for penalties related to unrecognized tax benefits 0 0 0                  
Operating Loss and Tax Credit Carryforwards [Line Items]                        
NOL carryforward         264,700,000 391,600,000 595,100,000 566,800,000        
Federal tax credit carryforwards         16,200,000 15,500,000            
State tax credit carryforwards, net of federal detriment             11,600,000 9,400,000        
Carryforward expiration date range, low         2021   2015          
Carryforward expiration date range, high         2031   2031          
Effective Tax Rate Reconciliation [Abstract]                        
Federal statutory rate (in hundredths) 35.00% 35.00% 35.00%                  
Increases (Decreases) in Tax From [Abstract]                        
Prescription drug tax benefit and Medicare Part D (in hundredths) (2.50%) (0.10%) 1.60%                  
Tax credits recognized, net of federal income tax expense (in hundredths) (0.60%) (0.80%) (0.80%)                  
Regulatory differences - utility plant items (in hundredths) (0.60%) (0.20%) (0.50%)                  
State income taxes, net of federal income tax benefit (in hundredths) 2.30% 2.50% 1.00%                  
Change in unrecognized tax benefits (in hundredths) 0.10% (0.10%) 0.00%                  
Life insurance policies (in hundredths) 0.00% 0.00% (1.40%)                  
Other, net (in hundredths) 0.00% 0.20% 1.50%                  
Effective income tax rate from continuing operations (in hundredths) 33.70% 36.50% 36.40%                  
Components of Income Tax Expense [Abstract]                        
Current federal tax expense 176,354,000 1,889,000 76,228,000                  
Current state tax expense (benefit) 24,502,000 (796,000) (461,000)                  
Current change in unrecognized tax (benefit) expense (3,447,000) 3,326,000 1,246,000                  
Deferred federal tax expense 38,309,000 207,620,000 146,501,000                  
Deferred state tax (benefit) expense (4,424,000) 22,994,000 9,280,000                  
Deferred change in unrecognized tax expense (benefit) 4,207,000 (4,059,000) (920,000)                  
Deferred investment tax credits (2,957,000) (2,613,000) (2,693,000)                  
Total income tax expense 232,544,000 228,361,000 229,181,000                  
Components of Deferred Income Tax Expense [Abstract]                        
Deferred tax expense excluding items below 41,233,000 216,393,000 160,543,000                  
Tax benefit allocated to other comprehensive income 6,433,000 12,149,000 393,000                  
Amortization and adjustments to deferred income taxes on income tax regulatory assets and liabilities (9,574,000) (1,987,000) (6,075,000)                  
Deferred tax expense 38,092,000 226,555,000 154,861,000                  
Deferred Tax Liabilities [Abstract]                        
Differences between book and tax bases of property 1,838,065,000 1,823,058,000                    
Employee benefits 99,286,000 130,544,000                    
Other 128,453,000 113,489,000                    
Total deferred tax liabilities 2,065,804,000 2,067,091,000                    
Deferred Tax Assets [Abstract]                        
NOL carryforward 129,829,000 169,688,000                    
Unbilled revenue - fuel costs 54,353,000 61,118,000                    
Tax credit carryforward 27,752,000 24,972,000                    
Deferred investment tax credits 15,992,000 16,985,000                    
Regulatory liabilities 14,164,000 14,693,000                    
Other 40,382,000 37,536,000                    
Total deferred tax assets 282,472,000 324,992,000                    
Net deferred tax liability $ 1,783,332,000 $ 1,742,099,000